HOSPITALIZATION, EDUCATION, AND OPTIMIZATION OF TOPICAL THERAPY CAN LEAD TO THE EARLY DISCONTINUATION OF ORAL JAK INHIBITORS IN ADOLESCENT SEVERE ATOPIC DERMATITIS

DOI Web Site PubMed
  • Omori Marei
    Allergy Center, National Center for Child Health and Development
  • Yamamoto-Hanada Kiwako
    Allergy Center, National Center for Child Health and Development
  • Umezawa Kotaro
    Allergy Center, National Center for Child Health and Development
  • Hirai Seiko
    Allergy Center, National Center for Child Health and Development
  • Harama Daisuke
    Allergy Center, National Center for Child Health and Development
  • Hagino Kohei
    Allergy Center, National Center for Child Health and Development
  • Matsumoto Yasuaki
    Allergy Center, National Center for Child Health and Development
  • Suzuki Daichi
    Allergy Center, National Center for Child Health and Development
  • Ishikawa Fumi
    Allergy Center, National Center for Child Health and Development
  • Toyokuni Kenji
    Allergy Center, National Center for Child Health and Development
  • Fukuie Tatsuki
    Allergy Center, National Center for Child Health and Development
  • Ohya Yukihiro
    Allergy Center, National Center for Child Health and Development

Bibliographic Information

Other Title
  • 入院による教育と外用療法の適正化で経口JAK阻害剤を早期に終了できた思春期重症アトピー性皮膚炎症例
  • ニュウイン ニ ヨル キョウイク ト ガイヨウ リョウホウ ノ テキセイカ デ ケイコウ JAK ソガイザイ オ ソウキ ニ シュウリョウ デキタ シシュンキ ジュウショウ アトピーセイ ヒフ エンショウレイ

Search this article

Description

<p>In cases of moderate to severe atopic dermatitis that does not respond to topical therapy, temporary systemic administration of molecular targeted drugs (biological agents or oral Janus kinase[JAK]inhibitors) may be necessary. However, topical therapy forms the basis of the treatment for atopic dermatitis, and if topical therapy is appropriately established with long-term remission achieved, the use of molecular targeted drugs can be discontinued. In these two cases of severe adolescent atopic dermatitis, successful initiation of remission was achieved through hospitalization, disease education, skincare guidance, and the combined use of appropriate topical therapy and short-term oral JAK inhibitors during the remission induction phase. Subsequently, maintenance of remission was possible with proactive topical therapy alone. As there are many cases where molecular targeted drugs cannot be discontinued, presenting cases where oral JAK inhibitors were successfully discontinued emphasizes the avoidance of indiscriminate long-term use of molecular targeted drugs. This highlights the significance of topical therapy for atopic dermatitis and the importance of avoiding the careless use of molecular targeted drugs, and supporting the transition to adulthood.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top